Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure.

Lugnier C, Meyer A, Charloux A, Andrès E, Gény B, Talha S.

J Clin Med. 2019 Oct 21;8(10). pii: E1746. doi: 10.3390/jcm8101746. Review.

2.

Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.

Bollenbach M, Lugnier C, Kremer M, Salvat E, Megat S, Bihel F, Bourguignon JJ, Barrot M, Schmitt M.

Eur J Med Chem. 2019 Sep 1;177:269-290. doi: 10.1016/j.ejmech.2019.05.026. Epub 2019 May 22.

PMID:
31158744
3.

Effect of the Phosphodiesterase 5 Inhibitor Sildenafil on Ischemia-Reperfusion-Induced Muscle Mitochondrial Dysfunction and Oxidative Stress.

Tetsi L, Charles AL, Georg I, Goupilleau F, Lejay A, Talha S, Maumy-Bertrand M, Lugnier C, Geny B.

Antioxidants (Basel). 2019 Apr 7;8(4). pii: E93. doi: 10.3390/antiox8040093.

4.

Design, Synthesis, Pharmacological Evaluation and Vascular Effects of Delphinidin Analogues.

Legeay S, Trân K, Abatuci Y, Justiniano H, Lugnier C, Duval O, Helesbeux JJ, Faure S.

Curr Pharm Des. 2018;24(46):5580-5589. doi: 10.2174/1381612825666190206144913.

PMID:
30727871
5.

Mechanisms underlying vasorelaxation induced in the porcine coronary arteries by Thymus linearis, Benth.

Alamgeer, Auger C, Chabert P, Lugnier C, Mushtaq MN, Schini-Kerth VB.

J Ethnopharmacol. 2018 Oct 28;225:211-219. doi: 10.1016/j.jep.2018.07.010. Epub 2018 Jul 20.

PMID:
30009977
6.

Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families.

Abusnina A, Lugnier C.

Cell Signal. 2017 Nov;39:55-65. doi: 10.1016/j.cellsig.2017.07.018. Epub 2017 Jul 25. Review.

PMID:
28754627
7.

Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.

Tetsi L, Charles AL, Paradis S, Lejay A, Talha S, Geny B, Lugnier C.

Cell Mol Life Sci. 2017 May;74(10):1883-1893. doi: 10.1007/s00018-016-2446-0. Epub 2016 Dec 30. Review.

PMID:
28039524
8.

Endothelium-independent vasorelaxant effect of a Berberis orthobotrys root extract via inhibition of phosphodiesterases in the porcine coronary artery.

Alamgeer, Chabert P, Akhtar MS, Jabeen Q, Delecolle J, Heintz D, Garo E, Hamburger M, Auger C, Lugnier C, Kim HJ, Oak MH, Schini-Kerth VB.

Phytomedicine. 2016 Jul 15;23(8):793-9. doi: 10.1016/j.phymed.2016.04.005. Epub 2016 May 6.

PMID:
27288914
9.

Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells.

Keravis T, Favot L, Abusnina AA, Anton A, Justiniano H, Soleti R, Alabed Alibrahim E, Simard G, Andriantsitohaina R, Lugnier C.

PLoS One. 2015 Dec 22;10(12):e0145291. doi: 10.1371/journal.pone.0145291. eCollection 2015.

10.

Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.

Clauss F, Charloux A, Piquard F, Doutreleau S, Talha S, Zoll J, Lugnier C, Geny B.

Fundam Clin Pharmacol. 2015 Aug;29(4):352-61. doi: 10.1111/fcp.12124. Epub 2015 May 25.

PMID:
25939307
11.

Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.

Abusnina A, Keravis T, Zhou Q, Justiniano H, Lobstein A, Lugnier C.

Thromb Haemost. 2015 Feb;113(2):319-28. doi: 10.1160/TH14-05-0454. Epub 2014 Sep 18.

PMID:
25230992
12.

Cyclic GMP catabolism up-regulation in MRL/lpr lupus-prone mice is associated with organ remodeling.

Yougbaré I, Keravis T, Abusnina A, Decossas M, Schall N, Muller S, Lugnier C.

Biochim Biophys Acta. 2014 Jul;1842(7):916-26. doi: 10.1016/j.bbadis.2014.03.001. Epub 2014 Mar 12.

13.

NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production.

Yougbaré I, Boire G, Roy M, Lugnier C, Rouseau E.

Can J Physiol Pharmacol. 2013 May;91(5):353-61. doi: 10.1139/cjpp-2012-0233. Epub 2013 Jan 2.

PMID:
23656347
14.

Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.

Kümmerle AE, Schmitt M, Cardozo SV, Lugnier C, Villa P, Lopes AB, Romeiro NC, Justiniano H, Martins MA, Fraga CA, Bourguignon JJ, Barreiro EJ.

J Med Chem. 2012 Sep 13;55(17):7525-45. doi: 10.1021/jm300514y. Epub 2012 Aug 30.

PMID:
22891752
15.

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.

Keravis T, Monneaux F, Yougbaré I, Gazi L, Bourguignon JJ, Muller S, Lugnier C.

PLoS One. 2012;7(1):e28899. doi: 10.1371/journal.pone.0028899. Epub 2012 Jan 11.

16.

Endothelium-independent and endothelium-dependent vasorelaxation by a dichloromethane fraction from Anogeissus Leiocarpus (DC) Guill. Et Perr. (Combretaceae): possible involvement of cyclic nucleotide phosphodiesterase inhibition.

Belemnaba L, Ouédraogo S, Auger C, Chataigneau T, Traore A, Guissou IP, Lugnier C, Schini-Kerth VB, Bucher B.

Afr J Tradit Complement Altern Med. 2012 Dec 31;10(2):173-9. eCollection 2013.

17.

Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.

Kolli-Bouhafs K, Boukhari A, Abusnina A, Velot E, Gies JP, Lugnier C, Rondé P.

Invest New Drugs. 2012 Dec;30(6):2121-31. doi: 10.1007/s10637-011-9777-3. Epub 2011 Dec 15.

PMID:
22170088
18.

Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.

Abusnina A, Keravis T, Yougbaré I, Bronner C, Lugnier C.

Mol Nutr Food Res. 2011 Nov;55(11):1677-89. doi: 10.1002/mnfr.201100307. Epub 2011 Sep 21.

PMID:
22045655
19.

PDE inhibitors: a new approach to treat metabolic syndrome?

Lugnier C.

Curr Opin Pharmacol. 2011 Dec;11(6):698-706. doi: 10.1016/j.coph.2011.09.012. Epub 2011 Oct 19. Review.

PMID:
22018840
21.

New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam.

Bihel FJ, Justiniano H, Schmitt M, Hellal M, Ibrahim MA, Lugnier C, Bourguignon JJ.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6567-72. doi: 10.1016/j.bmcl.2011.08.036. Epub 2011 Aug 12.

PMID:
21920746
22.

NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

Yougbare I, Morin C, Senouvo FY, Sirois C, Albadine R, Lugnier C, Rousseau E.

Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L441-50. doi: 10.1152/ajplung.00407.2010. Epub 2011 Jul 22.

23.

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C.

PLoS One. 2010 Dec 3;5(12):e14227. doi: 10.1371/journal.pone.0014227.

24.

Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis.

Abusnina A, Alhosin M, Keravis T, Muller CD, Fuhrmann G, Bronner C, Lugnier C.

Cell Signal. 2011 Jan;23(1):152-60. doi: 10.1016/j.cellsig.2010.08.015. Epub 2010 Aug 31.

PMID:
20807569
25.

Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.

Brito FC, Kummerle AE, Lugnier C, Fraga CA, Barreiro EJ, Miranda AL.

Eur J Pharmacol. 2010 Jul 25;638(1-3):5-12. doi: 10.1016/j.ejphar.2010.04.003. Epub 2010 Apr 20.

PMID:
20412790
26.

The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species.

Guabiraba R, Campanha-Rodrigues AL, Souza AL, Santiago HC, Lugnier C, Alvarez-Leite J, Lemos VS, Teixeira MM.

Eur J Pharmacol. 2010 May 10;633(1-3):85-92. doi: 10.1016/j.ejphar.2010.01.021. Epub 2010 Feb 10.

PMID:
20152831
27.

Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.

Keravis T, Lugnier C.

Curr Pharm Des. 2010;16(9):1114-25. Review.

PMID:
20030615
28.

Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1.

Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J, Chataigneau T, Lugnier C, Schini-Kerth VB, Bronner C, Fuhrmann G.

Biochem Pharmacol. 2010 May 1;79(9):1251-60. doi: 10.1016/j.bcp.2009.12.015. Epub 2009 Dec 22.

PMID:
20026309
29.

Hamartin variants that are frequent in focal dysplasias and cortical tubers have reduced tuberin binding and aberrant subcellular distribution in vitro.

Lugnier C, Majores M, Fassunke J, Pernhorst K, Niehusmann P, Simon M, Nellist M, Schoch S, Becker A.

J Neuropathol Exp Neurol. 2009 Oct;68(10):1136-46. doi: 10.1097/NEN.0b013e3181b9a699.

PMID:
19918125
30.

PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Tahseldar-Roumieh R, Keravis T, Maarouf S, Justiniano H, Sabra R, Lugnier C.

Int J Exp Pathol. 2009 Dec;90(6):605-14. doi: 10.1111/j.1365-2613.2009.00678.x. Epub 2009 Sep 15.

31.

Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.

Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C, Samuel JL, Lugnier C, Conti M, Fischmeister R, Vandecasteele G.

Circ Res. 2009 Oct 9;105(8):784-92. doi: 10.1161/CIRCRESAHA.109.197947. Epub 2009 Sep 10.

32.

The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue.

Gonçalves RL, Lugnier C, Keravis T, Lopes MJ, Fantini FA, Schmitt M, Cortes SF, Lemos VS.

Eur J Pharmacol. 2009 Oct 12;620(1-3):78-83. doi: 10.1016/j.ejphar.2009.08.008. Epub 2009 Aug 15.

PMID:
19686719
33.

Application of drug repositioning strategy to TOFISOPAM.

Bernard P, Dufresne-Favetta C, Favetta P, Do QT, Himbert F, Zubrzycki S, Scior T, Lugnier C.

Curr Med Chem. 2008;15(30):3196-203.

PMID:
19075663
34.

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C.

Br J Pharmacol. 2008 May;154(1):82-92. doi: 10.1038/bjp.2008.56. Epub 2008 Mar 3.

35.

Biflavones of Decussocarpus rospigliosii as phosphodiesterases inhibitors.

Chaabi M, Antheaume C, Weniger B, Justiniano H, Lugnier C, Lobstein A.

Planta Med. 2007 Oct;73(12):1284-6. Epub 2007 Sep 24.

PMID:
17893835
36.

Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere.

Raboisson P, Schultz D, Muller C, Reimund JM, Pinna G, Mathieu R, Bernard P, Do QT, Desjarlais RL, Justiano H, Lugnier C, Bourguignon JJ.

Eur J Med Chem. 2008 Apr;43(4):816-29. Epub 2007 Jun 8.

PMID:
17640774
37.

Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin.

Do QT, Renimel I, Andre P, Lugnier C, Muller CD, Bernard P.

Curr Drug Discov Technol. 2005 Sep;2(3):161-7.

PMID:
16472225
38.

Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis.

Tahseldar-Roumieh R, Ghali-Ghoul R, Lugnier C, Sabra R.

Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H481-8.

39.

Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta.

Alvarez E, Campos-Toimil M, Justiniano-Basaran H, Lugnier C, Orallo F.

Br J Pharmacol. 2006 Feb;147(3):269-80.

40.

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

Lugnier C.

Pharmacol Ther. 2006 Mar;109(3):366-98. Epub 2005 Aug 15. Review.

PMID:
16102838
41.

Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.

Keravis T, Thaseldar-Roumié R, Lugnier C.

Methods Mol Biol. 2005;307:63-74.

PMID:
15988055
42.

Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor.

Krier M, Araújo-Júnior JX, Schmitt M, Duranton J, Justiano-Basaran H, Lugnier C, Bourguignon JJ, Rognan D.

J Med Chem. 2005 Jun 2;48(11):3816-22.

PMID:
15916433
43.

Bioactive triterpenoids from Vochysia pacifica interact with cyclic nucleotide phosphodiesterase isozyme PDE4.

Weniger B, Lobstein A, Um BH, Vonthron-Sénéchau C, Anton R, Usuga NJ, Basaran H, Lugnier C.

Phytother Res. 2005 Jan;19(1):75-7.

PMID:
15798995
44.

Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites.

Ahloulay M, Bankir L, Lugnier C, Le Bec A, Poirel O, Moreau R, Lebrec D.

Liver Int. 2005 Apr;25(2):403-9.

PMID:
15780066
45.
46.

Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin.

Orallo F, Alvarez E, Basaran H, Lugnier C.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):452-63. Epub 2004 Nov 17.

PMID:
15599707
47.

Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels.

Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet JL, Cooper DM, Fischmeister R.

J Biol Chem. 2004 Dec 10;279(50):52095-105. Epub 2004 Oct 1.

48.
49.

Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.

Moreno L, Losada B, Cogolludo Al, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Pérez-Vizcaíno F.

Pediatr Res. 2004 Oct;56(4):563-70. Epub 2004 Aug 4.

PMID:
15295092
50.

Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.

Gouault N, Martin-Chouly CA, Lugnier C, Cupif JF, Tonnelier A, Feger F, Lagente V, David M.

J Pharm Pharmacol. 2004 Aug;56(8):1029-37.

PMID:
15285848

Supplemental Content

Loading ...
Support Center